Breaking News
Get 40% Off 0
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool. See stock ideas
Close

Generation Bio Co (GBIO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Generation Bio's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.990 -0.270    -8.28%
10/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.990
0.000
0.00%
16:02:21 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 117,915
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.990 - 3.290
Generation Bio 2.990 -0.270 -8.28%

Generation Bio Co Company Profile

 
Get an in-depth profile of Generation Bio Co, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

150

Equity Type

ORD

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 301 Binney Street
Cambridge, 02142
United States
Phone 617 655 7500
Fax -

Top Executives

Name Age Since Title
Jason P. Rhodes 51 2017 Independent Chairman
Charles A. Rowland 63 2018 Independent Director
Andrew M. Scharenberg - - Chairman of Scientific Advisory Board
Cameron Geoffrey McDonough 53 2017 President, CEO & Director
Adrian Thrasher - - Member of Scientific Advisory Board
Jeffrey M. Jonas 70 2018 Independent Director
Kevin Joseph Fitzgerald 54 - Member of Scientific Advisory Board
Katherine Fitzgerald - 2019 Member of Scientific Advisory Board
Ronald H. W. Cooper 60 2021 Independent Director
Richard Thompson - 2018 Member of Scientific Advisory Board
Donald William Nicholson 65 2017 Independent Director
Catherine Stehman-Breen 60 2017 Independent Director
Anthony G. Quinn 61 2017 Independent Director
Gustav A. Christensen 75 2017 Independent Director
Steven F. Dowdy - 2019 Member of Scientific Advisory Board
Dannielle Appelhans 40 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GBIO Comments

Write your thoughts about Generation Bio Co
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
vikram singh Panwar
vikram singh Panwar Dec 06, 2022 10:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target 15 in 2 month
Ugochukwu Nwalozie
Ugochukwu Nwalozie Dec 15, 2021 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$27 target price
stock Fckr
stock Fckr Jul 14, 2020 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any target price ?
Mohanad Said
Mohanad Said Jul 14, 2020 11:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
5.50
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email